Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Cerevel Therapeutics

Status and phase: Completed; Phase 1

Conditions: Schizophrenia

Treatments: Drug: 30 mg CVL-231 Target Release, Fed; Drug: 30 mg CVL-231 Target Release, Fasted; Drug: 30 mg CVL-231 as fast release MR formulation; Drug: 30 mg CVL-231 as slow-release MR formulation; Drug: 30 mg CVL-231 as medium release MR formulation; Drug: 10 mg CVL-231 as IR formulation

Study type: Interventional

Funder types: Industry

Identifiers

NCT05106309

CVL-231-1004

Details and patient eligibility

About

A 2-part, crossover design, open-label treatment trial with 4 periods, 4 sequences (Part A) to evaluate MR formulations of CVL-231 and a 2 periods, 2 sequences (Part B) to understand effect of food on CVL-231 exposures from an MR formulation.

Full description

CVL-231 is a muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype (M4 mAChR) and is being developed for treatment of psychosis in schizophrenia. Part A of this 2-part trial will investigate the PK of CVL-231 in healthy participants following a single oral dose of CVL-231 as 3 modified-release (MR) formulations with different release rates and an immediate-release (IR) formulation under fasted conditions. Upon selection of an MR formulation with appropriate PK characteristics, the effect of food on the PK of CVL-231 and its metabolite following single oral doses of the selected MR formulation may be evaluated in Part B.

Enrollment: 16 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Women of nonchildbearing potential and men 18 to 55 years, inclusive.
2. Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, ECG, vital sign measurements, and laboratory test results, as evaluated by the investigator.
3. Body mass index of 18.5 to 30.0 kg/m2 and a total body weight >50 kg (110 lbs).
4. Sexually active men with a pregnant or a nonpregnant partner of childbearing potential must agree to comply with protocol contraception requirements during treatment and through 7 days post dose. In addition, male participants should not donate sperm for a minimum of 7 days following the last dose of IMP.
5. Capable of giving signed informed consent.
6. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements.

Exclusion criteria

1. Current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine, hematological, immunological, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.

2. Current or past personal or family history of any psychiatric disorder as classified by DSM-5 criteria.

3. Epilepsy or a history of seizures except for a single seizure episode, eg, a childhood febrile seizure, a seizure related to trauma or alcohol withdrawal, or an unexplained loss of consciousness.

4. History of moderate to severe substance or alcohol-use disorder (excluding caffeine) within 12 months prior to signing the ICF.

5. Serious risk of suicide in the opinion of the investigator

6. Receipt of SARS-CoV2 vaccine or booster within 28 days of dosing with CVL-231, or plan to receive SARS-CoV2 vaccination or booster from Screening through 5 days after last dose of CVL-231.

7. Have recently been diagnosed with symptomatic COVID-19 or test positive for COVID-19 within 30 days prior to signing the ICF.

8. Either of the following:

   • History of HIV, hepatitis B, or hepatitis C infection
   • Positive result for HIV antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody

9. Positive drug screen for illicit drugs or a positive test for alcohol

10. 12-lead ECG demonstrating pre-defined abnormalities at Screening and Day -1 based on local evaluation.

11. Abnormal clinical laboratory tests or vital sign measurements at the Screening Visit and at Day -1 (check-in) for each period

12. Known to be allergic or hypersensitive to the IMP or any of its components.

13. Participation in any clinical trial within 90 days prior to signing the ICF.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

16 participants in 2 patient groups

Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditions

Experimental group

Description:

Oral Dose

Treatment:

Drug: 30 mg CVL-231 as slow-release MR formulation

Drug: 30 mg CVL-231 as medium release MR formulation

Drug: 30 mg CVL-231 as fast release MR formulation

Drug: 10 mg CVL-231 as IR formulation

Part B: Single doses of CVL-231 target release formulation under fasted and fed conditions

Experimental group

Description:

Oral Dose

Treatment:

Drug: 30 mg CVL-231 Target Release, Fed

Drug: 30 mg CVL-231 Target Release, Fasted